Andelyn Biosciences Capacity Update October 2025: Cell & Gene Therapy

A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, emphasizing a practical implementation approach that considers factors such as product contact level, material classification, and stage of manufacturing to ensure quality, compliance, and process consistency throughout development and production.